Stocks · News reference

Glucotrack Stock Is Trending: Here's Why GCTK Jumped Over 80% After Hours

Sep 24, 2026, 3:14 AMMohd Haider

GlucoTrack shares soar 80% after-hours as Lokahi Therapeutics signs first external glioblastoma licensing partnership with Innovate GBM.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 25, 2026, 2:11 PMBenzinga Newsdesk
Glucotrack shares are trading lower. The company announced its subsidiary Lōkahi Therapeutics will partner with Pepperdine E2B to engage students in its ai2 Pipeline initiative during the upcoming academic year.
GCTK
BenzingaSep 25, 2026, 1:02 PMBenzinga Newsdesk
Glucotrack's Lōkahi Therapeutics Announces Partnership With Pepperdine Business School For MBA Students To Evaluate Drug Assets
GCTK
SEC EDGARSep 24, 2026, 9:15 PMSEC EDGAR
8-K filing — Glucotrack, Inc. (GCTK)
Filed: 2026-09-24 AccNo: 0001493152-26-044182 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
GCTK
BenzingaSep 24, 2026, 3:39 PMLekha Gupta
What's Going On With GlucoTrack Shares On Thursday?
GlucoTrack subsidiary Lokahi Therapeutics secured its first external fee-for-service partnership with nonprofit Innovate GBM for glioblastoma research.
GCTK